These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 20404000)

  • 1. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two good choices to prevent breast cancer: great taste, less filling.
    Hortobagyi GN; Brown PH
    Cancer Prev Res (Phila); 2010 Jun; 3(6):681-5. PubMed ID: 20522797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
    Vogel VG
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).
    Cuzick J
    Cancer Prev Res (Phila); 2010 Jun; 3(6):689-91. PubMed ID: 20522799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene: a review of its use in the prevention of invasive breast cancer.
    Moen MD; Keating GM
    Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
    Nelson HD; Smith ME; Griffin JC; Fu R
    Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
    Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L
    Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene: risks and benefits.
    Barrett-Connor E
    Ann N Y Acad Sci; 2001 Dec; 949():295-303. PubMed ID: 11795366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.